title: Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells.
abstract: Bone marrow cells expressing the surface antigen CD34 comprise approximately 1% of harvested marrow and are highly enriched for marrow progenitor cells, including the cells believed to be responsible for long-term engraftment following bone marrow transplantation (BMT). Selection of CD34-expressing cells was applied in allogeneic BMT (alloBMT) to decrease the number of T lymphocytes in the infused marrow in an attempt to prevent severe graft-versus-host disease (GVHD). We report 14 patients who underwent HLA-identical sibling-matched alloBMT with marrow-enriched for CD34 cells using the Isolex 300 SA device. Patients received total body irradiation, thiotepa, cyclophosphamide, antithymocyte globulin and methylprednisolone prior to marrow infusion. No post-transplantation immunosuppressive therapy was given except for a 5-week course of steroids. The purity of the infused marrow was 64.9+/-6.0% (mean +/- s.e.m.) CD34-positive cells and patients received a mean of 1.24+/-0.21 x 10(6) CD34 cells/kg. A mean of 9.4+/-1.7 x 10(4) CD3 T cells/kg were present in the CD34-enriched product, representing a 2.7+/-0.1 log depletion. There were no graft rejections and patients achieved a sustained absolute granulocyte count of >500 in a median of 10.5 days and a sustained platelet engraftment of >20000 untransfused in a median of 27 days. Patients were discharged a median of 21.5 days after marrow infusion. There were no instances of grade III or IV graft-versus-host disease (GVHD) and no unexpected adverse events during the transplant hospitalization. With a median follow-up of 12 months, the estimated 100 day survival is 86+/-9%. CD34 selection in alloBMT permits rapid engraftment without unanticipated toxicities.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.
authors.forename: K
authors.initials: K
authors.lastname: Cornetta
authors.forename: V
authors.initials: V
authors.lastname: Gharpure
authors.forename: B
authors.initials: B
authors.lastname: Mills
authors.forename: R
authors.initials: R
authors.lastname: Hromas
authors.forename: R
authors.initials: R
authors.lastname: Abonour
authors.forename: E R
authors.initials: ER
authors.lastname: Broun
authors.forename: C M
authors.initials: CM
authors.lastname: Traycoff
authors.forename: M
authors.initials: M
authors.lastname: Hanna
authors.forename: N
authors.initials: N
authors.lastname: Wyman
authors.forename: C
authors.initials: C
authors.lastname: Danielson
authors.forename: R
authors.initials: R
authors.lastname: Gonin
authors.forename: L K
authors.initials: LK
authors.lastname: Kunkel
authors.forename: F
authors.initials: F
authors.lastname: Oldham
authors.forename: E F
authors.initials: EF
authors.lastname: Srour
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D014184:Transplantation, Homologous
chemical_list: D018952:Antigens, CD34